Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Open to Accrual
Activation Date: August 25, 2020
To compare the clinical complete response rate [cCR] after chemoRT with or without MEDI4736 (durvalumab) in node-positive bladder cancer patients.
This is a Joint ECOG/ACRIN & NRG Oncology trial, with ECOG-ACRIN as the lead group for trial conduct. NRG Oncology institutions can credit NRG for their case accrual.
ECOG-ACRIN Study Chair: Monika Joshi, MD, MRCP
Patient with histologically proven pure or mixed urothelial cancer of the bladder (any T, N1-2 M0).
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.